San Diego, CA-based Cue offers an undeniably sleek product that looks like it would fit into the tech-savvy aesthetic of an early adopter's home. According to information on the corporate website, the device tracks patient health indicators for inflammation, vitamin D, fertility, influenza, and testosterone using a nasal swab, saliva, or drop of blood. 

The small device, which company press materials describe as investigational and not for diagnostic use, works with single-use cartridges and sends data to the user via a smartphone app.

In February 2016, Cue announced it is working with Janssen Pharmaceuticals to broaden access to HIV viral load testing in developing countries. The device's small size, digital and connected capabilities, cost, and simple approach make it well suited for "resource poor settings," according to a press release.

Cue CEO Ayub Khattak said in the release, "We're excited to work with Janssen, a leader in the HIV field, to accelerate the development of the HIV quantitative viral load test on Cue's platform. Together we can make a big impact on this significant global health challenge by bringing simplicity, immediacy and affordability to the field of HIV viral load testing in an unprecedented way." 

Learn more about "Digital Health Opportunities: Patient Populations and Markets Around the World" during the BIOMEDevice San Jose Conference and Expo, December 7-8.